Peanut Allergy Biotech DBV Technologies Sets Terms For $98 Million U.S. IPO

Published: Oct 16, 2014

DBV Technologies, a French biotech developing immunotherapy patches that treat food allergies, announced terms for its US IPO on Wednesday. The Bagneux, France-based company is currently listed on the Euronext Paris under the symbol DBV. It plans to offer 4.3 million ADSs, and at $23 per ADS, the price as of October 14, DBV Technologies would command a fully diluted market value of $964 million.

Help employers find you! Check out all the jobs and post your resume.

Back to news